Adhera Therapeutics, Inc.: 10-Q filed 2023-11-20
What Adhera Therapeutics, Inc. reported in its quarterly report filed 2023-11-20 (fiscal Q3 2023): 26 published measures, 83 facts as tagged in accession 0001493152-23-042138.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2023-11-20
- Fiscal period
- fiscal Q3 2023
- Accession
- 0001493152-23-042138 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All Adhera Therapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 44,074 | USD | |
| At 2022-12-31 | 78,511 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 26,359,515 | USD | |
| At 2022-12-31 | 22,264,061 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | -26,315,441 | USD | |
| At 2023-06-30 | -22,787,224 | USD | |
| At 2023-03-31 | -23,092,723 | USD | |
| At 2022-12-31 | -22,185,550 | USD | |
| At 2022-09-30 | -21,805,438 | USD | |
| At 2022-06-30 | -19,993,380 | USD | |
| At 2022-03-31 | -25,497,550 | USD | |
| At 2021-12-31 | -25,105,618 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -3,535,815 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -4,150,375 | USD | 273 |
| 2023-04-01 to 2023-06-30 | 271,279 | USD | 91 |
| 2023-01-01 to 2023-03-31 | -885,839 | USD | 90 |
| 2022-07-01 to 2022-09-30 | -1,803,352 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -1,778,796 | USD | 273 |
| 2022-04-01 to 2022-06-30 | 98,286 | USD | 91 |
| 2022-01-01 to 2022-03-31 | -73,730 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -655,155 | USD | 273 |
| 2022-01-01 to 2022-09-30 | -1,355,962 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 655,782 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 1,413,246 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | -59,980,637 | USD | |
| At 2022-12-31 | -55,750,381 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 4,303,866 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 3,649,428 | shares | 273 |
| 2022-07-01 to 2022-09-30 | 3,160,877 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 2,019,953 | shares | 273 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 4,303,866 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 3,649,428 | shares | 273 |
| 2022-07-01 to 2022-09-30 | 3,160,877 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 2,019,953 | shares | 273 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -0.83 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | -1.16 | USD/shares | 273 |
| 2022-07-01 to 2022-09-30 | -0.57 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | -1.17 | USD/shares | 273 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -0.83 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | -1.16 | USD/shares | 273 |
| 2022-07-01 to 2022-09-30 | -0.57 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | -1.17 | USD/shares | 273 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 143,238 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 429,396 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 154,161 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 304,161 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -269,497 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -917,521 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -547,570 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -1,256,290 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 44,074 | USD | |
| At 2022-12-31 | 78,511 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 26,359,515 | USD | |
| At 2022-12-31 | 22,264,061 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 2,351,653 | USD | |
| At 2022-12-31 | 2,396,716 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 269,497 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 917,521 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 547,570 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 1,256,290 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 5,168,912 | shares | |
| At 2022-12-31 | 3,160,877 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 33,636,179 | USD | |
| At 2022-12-31 | 33,547,890 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 5,545,905 | USD | |
| At 2022-12-31 | 4,372,366 | USD |
Current contract liabilities
Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-09-30 | 100,000 | USD |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -3,562,735 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -4,230,256 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -1,812,058 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -2,353,502 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | 42,992 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 148,153 | USD | 273 |
| 2022-07-01 to 2022-09-30 | 224,243 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 430,268 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-07-01 to 2023-09-30 | -3,266,318 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -3,232,854 | USD | 273 |
| 2022-07-01 to 2022-09-30 | -1,255,782 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -522,506 | USD | 273 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | 17,513 | USD | 273 |
| 2022-01-01 to 2022-09-30 | 117,301 | USD | 273 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-09-30 | -8,739 | USD | 273 |
| 2022-01-01 to 2022-09-30 | -38,167 | USD | 273 |
Inspect the source
- Entity
- Adhera Therapeutics, Inc. / CIK 0000737207
- Captured
- SEC response SHA-256
b4aa163aa5766f2d921484473caaa9f0b2c20249a855398a2d3c8607f35860b4
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000737207.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))